Latest & greatest articles for amphetamine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amphetamine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amphetamine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amphetamine

1. Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. Full Text available with Trip Pro

Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. The prescription use of the stimulants methylphenidate and amphetamine for the treatment of attention deficit-hyperactivity disorder (ADHD) has been increasing. In 2007, the Food and Drug Administration mandated changes to drug labels for stimulants on the basis of findings of new-onset psychosis. Whether the risk of psychosis in adolescents and young adults with ADHD differs among various stimulants has not been extensively (...) studied.We used data from two commercial insurance claims databases to assess patients 13 to 25 years of age who had received a diagnosis of ADHD and who started taking methylphenidate or amphetamine between January 1, 2004, and September 30, 2015. The outcome was a new diagnosis of psychosis for which an antipsychotic medication was prescribed during the first 60 days after the date of the onset of psychosis. To estimate hazard ratios for psychosis, we used propensity scores to match patients who

2019 NEJM

2. Amphetamine

Amphetamine Top results for amphetamine - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for amphetamine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

3. Clandestine Amphetamine-Derived Drug Laboratories: Remediation Guidelines for Residential Settings

Clandestine Amphetamine-Derived Drug Laboratories: Remediation Guidelines for Residential Settings REVISED DECEMBER 2012 1 Clandestine Amphetamine-Derived Drug Laboratories: Remediation Guidelines for Residential Settings Prabjit Barn, Michele Wiens, Patti Dods Summary • Clandestine labs produce illegal substances using a variety of chemicals and manufacturing processes. • Clandestine labs can be housed in a variety of structures, including residential and non-residential buildings (...) . In particular, residential buildings previously used for clandestine labs can pose health concerns to re-occupants. • Amphetamine-derived drug labs are the most common type of clandestine lab found in most provinces. • Here we present guidelines on the remediation of clandestine amphetamine-derived drug labs for the purposes of protecting the health of re-occupants. These guidelines do not address other health hazards that may be encountered during cleanup. a • These guidelines are derived from instructions

2012 National Collaborating Centre for Environmental Health

4. Treatment for amphetamine psychosis. Full Text available with Trip Pro

Treatment for amphetamine psychosis. Chronic amphetamine users may have experience of paranoia and hallucination. It has long been believed that dopamine antagonists, such as chlorpromazine, haloperidol, and thioridazine, are effective for the treatment of amphetamine psychosis.To evaluate risks, benefits, costs of treatments for amphetamine psychosis.MEDLINE (1966-2007), EMBASE (1980-2007), CINAHL (1982-2007), PsychINFO (1806-2007), CENTRAL (Cochrane Library 2008 issue 1), references (...) of obtained articles.All randomised controlled and clinical trials (RCTs, CCTs) evaluating treatments (alone or combined) for people with amphetamine psychosisTwo authors evaluated and extracted the data independently. Dichotomous data were extracted on an intention-to-treat basis in which the dropouts were assigned as participants with the worst outcomes. The Relative Risk (RR) with the 95% confidence interval (95% CI) was used to assess the dichotomous data. The Weighted Mean Difference (WMD) with 95

2009 Cochrane

5. Speeding stroke recovery: a systematic review of amphetamine after stroke

Speeding stroke recovery: a systematic review of amphetamine after stroke Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

6. Review: limited evidence to support pharmacological therapy for amphetamine withdrawal Full Text available with Trip Pro

Review: limited evidence to support pharmacological therapy for amphetamine withdrawal Review: limited evidence to support pharmacological therapy for amphetamine withdrawal | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: limited evidence to support pharmacological therapy for amphetamine withdrawal Article Text Therapeutics Review: limited evidence to support pharmacological therapy for amphetamine withdrawal Free Michael

2009 Evidence-Based Mental Health

7. Treatment for amphetamine psychosis. (Abstract)

Treatment for amphetamine psychosis. Chronic amphetamine users may have experience of paranoia and hallucination. It has long been believed that dopamine antagonists, such as chlorpromazine, haloperidol, and thioridazine, are effective for the treatment of amphetamine psychosis.To evaluate risks, benefits, costs of treatments for amphetamine psychosis.MEDLINE (1966-2007), EMBASE (1980-2007), CINAHL (1982-2007), PsychINFO (1806-2007), CENTRAL (Cochrane Library 2008 issue 1), references (...) of obtained articles.All randomised controlled and clinical trials (RCTs, CCTs) evaluating treatments (alone or combined) for people with amphetamine psychosisTwo authors evaluated and extracted the data independently. Dichotomous data were extracted on an intention-to-treat basis in which the dropouts were assigned as participants with the worst outcomes. The Relative Risk (RR) with the 95% confidence interval (95% CI) was used to assess the dichotomous data. The Weighted Mean Difference (WMD) with 95

2008 Cochrane

8. What is the risk of AMI in amphetamine induced chest pain presenting to the ED?

What is the risk of AMI in amphetamine induced chest pain presenting to the ED? BestBets: What is the risk of AMI in amphetamine induced chest pain presenting to the ED? What is the risk of AMI in amphetamine induced chest pain presenting to the ED? Report By: Dr Bhavesh Papadi - SHO Medicine Search checked by Dr Karthikeyan Perumal - Radiation oncologist Institution: Chase Farm Hospital Date Submitted: 30th June 2007 Last Modified: 14th August 2008 Status: Green (complete) Three Part Question (...) In [patients presenting with chest pain following amphetamine use] what [is the incidence] of [acute myocardial infarction]? Clinical Scenario You are working in a very busy Accident and Emergency Department and the Triage Nurse informs you that, a patient with "Amphetamine induced chest pain" has just arrived. you wonder , what his chances are, to develop Acute Myocardial Infarction. Search Strategy Ovid MEDLINE(R) 1950 to March Week 2 2008 [exp Amphetamine-Related Disorders/or exp Amphetamine

2008 BestBETS

9. Mixed amphetamine salts - Attention deficit hyperactivity disorder

Mixed amphetamine salts - Attention deficit hyperactivity disorder Common Drug Review CEDAC Meeting – April 16, 2008; CEDAC Reconsideration – June 18, 2008 Page 1 of 3 Notice of CEDAC Final Recommendation – June 25, 2008 © 2008 CADTH CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION MIXED AMPHETAMINE SALTS (Adderall XR ® – Shire Canada Inc.) Description: Adderall XR ® contains dextroamphetamine and levoamphetamine salts in a 3:1 ratio. The Canadian Expert Drug (...) Advisory Committee had previously recommended that Adderall XR not be listed (see Notice of CEDAC Final Recommendation on Adderall XR issued on November 24, 2004). A new indication for use in adolescents and adults and new clinical trial information in children were the basis for the resubmission. Adderall XR is approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Dosage Forms: Capsules containing both immediate and extended release pellets of mixed amphetamine salts: 5 mg, 10

2008 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

10. Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. (Abstract)

Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. The consumption of psychostimulants for non-medical reasons probably occurs because of their euphoriant and psychomotor-stimulating properties. Chronic consumption of these agents results in development of stereotyped behaviour, paranoia, and possibly aggressive behaviour. Psychosocial treatments for psychostimulant use disorder are supposed to improve compliance, and to promote abstinence. Evidence from

2007 Cochrane

11. Adding mixed amphetamine salts to divalproex sodium improves ADHD symptoms in children with bipolar disorder and comorbid ADHD Full Text available with Trip Pro

Adding mixed amphetamine salts to divalproex sodium improves ADHD symptoms in children with bipolar disorder and comorbid ADHD Adding mixed amphetamine salts to divalproex sodium improves ADHD symptoms in children with bipolar disorder and comorbid ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adding mixed amphetamine salts to divalproex sodium improves ADHD symptoms in children with bipolar disorder and comorbid ADHD Article Text

2006 Evidence-Based Mental Health

12. Amphetamines for schizophrenia. (Abstract)

Amphetamines for schizophrenia. It is estimated that between 10% and 65% of people with schizophrenia use illicit drugs such as amphetamines. This group have an increased rate of hospitalisation, homelessness, unemployment and suicide compared with those with schizophrenia who do not abuse drugs.To evaluate the effects of amphetamines for people with schizophrenia in terms of clinically meaningful outcomes, cognitive functioning and physiological tests.We searched the Cochrane Schizophrenia (...) Group's Register (February 2002).We included all randomised controlled trials investigating the effects of amphetamines on people with schizophrenia, compared with a placebo intervention.Working independently, we selected and critically appraised studies, extracted data and analysed on an intention-to-treat basis. Where possible and appropriate we calculated risk ratios (RR) and their 95% confidence intervals (CI), with the number needed to treat (NNT). For continuous data we calculated Weighted Mean

2004 Cochrane

13. mixed amphetamine salts

mixed amphetamine salts CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION MIXED AMPHETAMINE SALTS EXTENDED RELEASE CAPSULES (Adderall XR™ – Shire BioChem Inc) Description: Adderall XR™ is an extended-release capsule containing d- and l-isomers of mixed amphetamine salts. The capsule contains two types of pellets in a 1:1 ratio, an immediate release pellet and a delayed release enteric coated form. Adderall XR™ is indicated for the treatment of attention deficit (...) hyperactivity disorder (ADHD). Recommendation: The Canadian Expert Drug Advisory Committee recommends that mixed amphetamine salts extended release capsules not be listed. Reasons for the Recommendation: 1. No head-to-head randomized controlled trials are available that compare mixed amphetamine salts extended release capsules with stimulants licensed in Canada – i.e. regular and sustained release formulations of methylphenidate, and dextroamphetamine. Therefore, the relative efficacy of mixed amphetamine

2004 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

14. Treatment for amphetamine withdrawal. (Abstract)

Treatment for amphetamine withdrawal. Amphetamine withdrawal has been less studied although it is a common problem with a prevalent rate of 87% among amphetamine users. Its symptoms, in particular intense craving, may be a critical factor leading to relapse of amphetamine use. In clinical practice, treatment for cocaine withdrawal has been recommended for the management of amphetamine withdrawal although the pharmacodynamic and pharmacokinetic properties of these two substances (...) are not the same.To search and determine risks, benefits, and costs of a variety of treatments for the management of amphetamine withdrawal.Electronic searches of MEDLINE (1966 - December 2000), EMBASE (1980 - February 2001), CINAHL (1982 - January 2001) and Cochrane Controlled Trials Register (Cochrane Library 2000 issue 4) were undertaken. References to the articles obtained by any means were searched.All relevant randomised controlled trials (RCTs) and controlled clinical trials (CCTs) were included

2001 Cochrane

15. Treatment for amphetamine dependence and abuse. (Abstract)

Treatment for amphetamine dependence and abuse. The ease of synthesis from inexpensive and readily available chemicals makes possible the wide spread of amphetamine dependence and abuse. Amphetamine use is of concern because it causes a variety of devastating health consequences, including physical and neurological disorders due to amphetamines, amphetamine-induced mental disorders, health consequences of amphetamine use and social consequences of amphetamine use.To search and determine risks (...) , benefits and costs of a variety treatments for amphetamine dependence or abuse.Electronic searches of MEDLINE (1966 - December 2000), EMBASE (1980 - February 2001), CINAHL (1982 - January 2001) and Cochrane Controlled Trials Register (Cochrane Library 2000 issue 4) were undertaken. References to the articles obtained by any means were searched.All relevant randomised controlled trials (RCTs) and clinical controlled trials (CCTs) were included. Participants were people with amphetamine dependence

2001 Cochrane

16. Treatment for amphetamine psychosis. (Abstract)

Treatment for amphetamine psychosis. During the phase of chronic, high-dose consumption of amphetamines, many amphetamine users may have the experience of paranoia and hallucination. It has long been believed that dopamine antagonists, such as chlorpromazine, haloperidol, and thioridazine, are effective for the treatment of amphetamine psychosis.To search and determine risks, benefits, and costs of a variety treatments for amphetamine psychosis.Electronic searches of MEDLINE (1966-2000), EMBASE (...) (1980-2000), CINAHL (1982- January 2001) and Cochrane Controlled Trials Register (Cochrane Library 2000 issue 4) were undertaken. References to the articles obtained by any means were searched.All relevant randomised controlled trials (RCTs) and clinical trials (CCTs) were included. Participants were people with amphetamine psychosis, diagnosed by any set of criteria. Any kinds of biological and psychological treatments both alone and combined were examined. A variety of outcomes, for example

2001 Cochrane